All In Biotech

Drug Trial Radar · NCT06468462

Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM

WHO-recommended Periodic Presumptive Treatment Versus Doxycycline Post-Exposure Prophylaxis for STI Control Among Cisgender Men Who Have Sex With Men in Kenya

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 2,900 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,900

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Oct 31, 2028

Study completion Apr 30, 2029

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aurum Institute; Nyanza Reproductive Health Society; National Institute of Allergy and Infectious Diseases (NIAID); Partners for Health & Development in Africa
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 29 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed. We propose an open-label randomized clinical trial with 2900 participants assigned to WHO-recommended periodic presumptive treatment (PPT) or doxycycline post-exposure prophylaxis (doxyPEP), compared to standard syndromic treatment, with 18 months of follow-up and rigorous culture-based and molecular analysis of antimicrobial resistance in Neisseria gonorrhoeae. This work will provide critical data needed to inform guidelines and improve STI control among MSM in sub-Saharan Africa and other resource-limited settings, including modelled estimates of the health and economic impact of scaling up these two interventions on STI control among MSM and their partners in Kenya.

Conditions

  • Gonorrhea Male
  • Chlamydia (Male)
  • Syphilis Male

Interventions

  • WHO-recommended periodic presumptive treatmentDrug

    400 mg po cefixime plus 1 gram azithromycin po under direct observation

  • Doxycycline post-exposure prophylaxisDrug

    200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with NG, CT, or early syphilis infection (combined STI outcome)Time frame: Over 18 months of follow-up at quarterly visits from the date of randomization

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Anza Mapema Clinic

    Kisumu, Kenya

  • University of Washington/Pwani Research Centre at the Ganjoni Municipal Clinic, Mombasa

    Mombasa, Kenya

  • TRANSFORM Clinic

    Nairobi, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.